US cancer death rate fall encourages PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) has expressed its encouragement from the release of data by the American Cancer Society concerning the decline of cancer death rates. Billy Tauzin, the PhRMA's president, who is also a cancer survivor, said: "the modest decline is further evidence that prevention, healthy lifestyles and proper treatments are effective methods in the fight against this deadly disease that touches so many Americans."
Mr Tauzin repeated his "strong support" for US President Barack Obama's call to "cure cancer in our lifetime." The PhRMA president added: "to achieve the President's lofty goal, the development of innovative new medicines is critically important. America's pharmaceutical research and biotechnology companies currently are developing 861 new medicines and vaccines to fight various forms of cancer. These include 122 for lung cancer...70 for colorectal cancer...and 103 for prostate cancer."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze